The DOI matches its Crossref record; 88 of the 89 references it cites were found in a registry or an index.
Artificial intelligence in COVID-19 drug repurposing
Open accessAbstract
Drug repurposing or repositioning is a technique whereby existing drugs are used to treat emerging and challenging diseases, including COVID-19. Drug repurposing has become a promising approach because of the opportunity for reduced development timelines and overall costs. In the big data era, artificial intelligence (AI) and network medicine offer cutting-edge application of information science to defining disease, medicine, therapeutics, and identifying targets with the least error. In this Review, we introduce guidelines on how to use AI for accelerating drug repurposing or repositioning, for which AI approaches are not just formidable but are also necessary. We discuss how to use AI models in precision medicine, and as an example, how AI models can accelerate COVID-19 drug repurposing. Rapidly developing, powerful, and innovative AI and network medicine technologies can expedite therapeutic development. This Review provides a strong rationale for using AI-based assistive tools for drug repurposing medications for human disease, including during the COVID-19 pandemic.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In some cases, these AI-powered approaches have been able to identify promising drug candidates in a fraction of the time that it would take when using traditional methods [26,27,28,29,30,31].”
From The role of AI in drug discovery: challenges, opportunities, and strategies (2023) · cites this paper as [28]
In the citing paper
“ML algorithms have been used to analyze large datasets of potential compounds and identify those with the most potential for treating the virus.”
From The role of AI in drug discovery: challenges, opportunities, and strategies (2023) · cites this paper as [28]
In the citing paper
“The study is a strong proof for the use of AI-assisted tools for drugs and repayment for human diseases, including COVID-19 in times of fatal disease [11].”
From Influential Usage of Big Data and Artificial Intelligence in Healthcare (2021) · cites this paper as [11]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
LeCun, Y., Bengio, Y., & Hinton, G. (2015) · Nature · doi:10.1038/nature14539 · Cited by 84,126
Learning representations by back-propagating errors
Rumelhart, D. E., Hinton, G. E., & Williams, R. J. (1986) · Nature · doi:10.1038/323533a0 · Cited by 31,892
The central role of the propensity score in observational studies for causal effects
ROSENBAUM, P. R., & RUBIN, D. B. (1983) · Biometrika · doi:10.1093/biomet/70.1.41 · Cited by 31,241
Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., Schiergens, T. S., Herrler, G., Wu, N.-H., Nitsche, A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.02.052 · Cited by 20,286
Dexamethasone in Hospitalized Patients with Covid-19
The RECOVERY Collaborative Group (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2021436 · Cited by 11,477
Effect of Dexamethasone in Hospitalized Patients with COVID-19 – Preliminary Report
Horby, P., Lim, W. S., Emberson, J., Mafham, M., Bell, J., Linsell, L., Staplin, N., Brightling, C., Ustianowski, A., Elmahi, E., et al. (2020) · doi:10.1101/2020.06.22.20137273 · Cited by 11,475
I.—COMPUTING MACHINERY AND INTELLIGENCE
TURING, A. M. (1950) · Mind · doi:10.1093/mind/lix.236.433 · Cited by 10,290
Remdesivir for the Treatment of Covid-19 — Final Report
Beigel, J. H., Tomashek, K. M., Dodd, L. E., Mehta, A. K., Zingman, B. S., Kalil, A. C., Hohmann, E., Chu, H. Y., Luetkemeyer, A., Kline, S., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2007764 · Cited by 7,267
Computing Machinery and Intelligence (1950)
Turing, A. M. (2004) · doi:10.1093/oso/9780198250791.003.0017 · Cited by 6,120
(2013) · Cited by 5,726
Cited by
Sorted by citations
The role of AI in drug discovery: challenges, opportunities, and strategies
Blanco-González, A., Cabezón, A., Seco-González, A., Conde-Torres, D., Antelo-Riveiro, P., Piñeiro, Á., & Garcia-Fandino, R. (2023) · Pharmaceuticals · doi:10.3390/ph16060891 · Cited by 690
The Ethics of Artificial Intelligence
Floridi, L. (2023) · doi:10.1093/oso/9780198883098.001.0001 · Cited by 682
Artificial intelligence in drug development
Zhang, K., Yang, X., Wang, Y., Yu, Y., Huang, N., Li, G. L., Li, X., Wu, J. C., & Yang, S. (2025) · Nature Medicine · doi:10.1038/s41591-024-03434-4 · Cited by 585
“An advanced pipeline has been created that integrates multimodal datasets, generates molecular leads using AI, ranks them by efficacy and safety, and uses deep reinforcement learning to create patentable analogs for testing 212 .”
Building a knowledge graph to enable precision medicine
Chandak, P., Huang, K., & Zitnik, M. (2023) · Scientific Data · doi:10.1038/s41597-023-01960-3 · Cited by 522
Artificial intelligence in cancer target identification and drug discovery
You, Y., Lai, X., Pan, Y. F., Zheng, H., Vera, J., Liu, S., Deng, S., & Zhang, L. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00994-0 · Cited by 499
“The key to identify therapeutic targets and discover drugs using ML-based biology analysis is to make use of network features in biological networks.”
BackgroundMethodDeep Learning applications for COVID-19
Shorten, C., Khoshgoftaar, T. M., & Furht, B. (2021) · Journal of Big Data · doi:10.1186/s40537-020-00392-9 · Cited by 350
“We refer readers to the illustrative diagram from their study [122] describing the integration of different data sources for Precision Diagnostics, shown in Fig.”
BackgroundMethodInfluentialZeng, X., Xiang, H., Yu, L., Wang, J., Li, K., Nussinov, R., & Cheng, F. (2022) · Nature Machine Intelligence · doi:10.1038/s42256-022-00557-6 · Cited by 322
“Benchmark evaluation of ImageMol We first evaluated the performance of ImageMol using eight types of benchmark dataset for drug discovery (Supplementary Tables 1–4): (1) molecular targets—human immunodeficiency virus (HIV), beta-secretase (BACE, a key target in Alzheimer’s disease) and maximum unbiased validation (17…”
MethodDeep generative molecular design reshapes drug discovery
Zeng, X., Wang, F., Luo, Y., Kang, S.-G., Tang, J., Lightstone, F. C., Fang, E. F., Cornell, W., Nussinov, R., & Cheng, F. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100794 · Cited by 295
Vișan, A. I., & Neguț, I. (2024) · Life · doi:10.3390/life14020233 · Cited by 333
“Yadi et al. [150] introduce guidelines on how to use AI for accelerating drug repurposing or repositioning.”
BackgroundA definition, benchmark and database of AI for social good initiatives
Cowls, J., Tsamados, A., Taddeo, M., & Floridi, L. (2021) · Nature Machine Intelligence · doi:10.1038/s42256-021-00296-0 · Cited by 226
Drug repurposing for COVID-19 via knowledge graph completion
Zhang, R., Hristovski, D., Schutte, D., Kastrin, A., Marcelo Fiszman, B., & Halil Kilicoglu, B. (2021) · Journal of Biomedical Informatics · doi:10.1016/j.jbi.2021.103696 · Cited by 237
“The potential of recent advances in artificial intelligence (AI) and machine learning for COVID-19 drug repurposing has also been highlighted [12] and several studies using these techniques have reported promising re-sults [13 – 16].”
Applications of artificial intelligence in COVID-19 pandemic: A comprehensive review
Khan, M., Mehran, M. T., Haq, Z. U., Ullah, Z., Naqvi, S. R., Ihsan, M., & Abbas, H. (2021) · Expert Systems with Applications · doi:10.1016/j.eswa.2021.115695 · Cited by 212
“It was identified by the network medicine analysis that Toremifene can significantly be used for treating COVID-19 disease (Zhou et al., 2020).”
Zhou, Y., Liu, Y., Gupta, S., Paramo, M. I., Hou, Y., Mao, C., Luo, Y., Judd, J., Wierbowski, S. D., Bertolotti, M., et al. (2022) · Nature Biotechnology · doi:10.1038/s41587-022-01474-0 · Cited by 214
AlphaFold, Artificial Intelligence (AI), and Allostery
Nussinov, R., Zhang, M., Liu, Y., & Jang, H. (2022) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.2c04346 · Cited by 190
Self-citationRobotics and artificial intelligence in healthcare during COVID-19 pandemic: a systematic review
Sarker, S., Jamal, L., Ahmed, S. F., & Irtisam, N. (2021) · Robotics and Autonomous Systems · doi:10.1016/j.robot.2021.103902 · Cited by 199
Deep learning for drug repurposing: Methods, databases, and applications
Pan, X., Lin, X., Cao, D., Zeng, X., Yu, P. S., He, L., Nussinov, R., & Cheng, F. (2022) · Wiley Interdisciplinary Reviews Computational Molecular Science · doi:10.1002/wcms.1597 · Cited by 202
“[2] Effective identification of new indications from approved or well-established clinical drugs plays an essential part in drug discovery.[3]-[6] Such a process is also known as drug repositioning or reprofiling, and it can bypass many preapproval tests required for newly developed therapeutic compounds.”
BackgroundMethodInfluentialDrug combination therapy for emerging viral diseases
Shyr, Z. A., Cheng, Y., Lo, D. C., & Zheng, W. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.05.008 · Cited by 191
Zhou, Y., Hou, Y., Shen, J., Mehra, R., Kallianpur, A., Culver, D. A., Gack, M. U., Farha, S., Zein, J., Comhair, S., et al. (2020) · PLoS Biology · doi:10.1371/journal.pbio.3000970 · Cited by 180
“Knowledge of the complex interplays between SARS-CoV-2 targets and human diseases indicate possibilities of drug repurposing, as the drugs that target other diseases could potentially target SARS-CoV-2 through the shared functional PPI networks [23].”
BackgroundSelf-citationTribulations and future opportunities for artificial intelligence in precision medicine
Carini, C., & Seyhan, A. A. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05067-0 · Cited by 221
“Numerous other examples highlight the capacity of AI-based methods to expedite drug screening and discovery [92] and enhance the development of more effective therapies, drug combinations for drug synergies [93, 94], and drug repurposing [88, 95–103] for various other diseases [104–110].”
BackgroundShaping the future of AI in healthcare through ethics and governance
Bouderhem, R. (2024) · Humanities and Social Sciences Communications · doi:10.1057/s41599-024-02894-w · Cited by 218
“Researchers discussed how AI systems could be used for repurposing or repositioning existing drugs which can help design new drug molecules or identify potential treatments for COVID-19 for instance (Zhou et al. 2020; Mohanty et al. 2020; Floresta et al. 2022).”
PharmKG: a dedicated knowledge graph benchmark for bomedical data mining
Zheng, S., Rao, J., Ying, S., Zhang, J., Xiao, X., Fang, E. F., Yang, Y., & Niu, Z. (2020) · Briefings in Bioinformatics · doi:10.1093/bib/bbaa344 · Cited by 171
“By integration with the disease-specific context, PharmKG can be further utilized to accelerate drug repurposing and mechanism analysis for emerging human diseases, such as COVID-19 [ 90].”
MethodZhou, Y., Xu, J., Hou, Y., Leverenz, J. B., Kallianpur, A. R., Mehra, R., Liu, Y., Yu, H., Pieper, A. A., Jehi, L. E., et al. (2021) · Alzheimer s Research & Therapy · doi:10.1186/s13195-021-00850-3 · Cited by 165
Drug repurposing for COVID-19: Approaches, challenges and promising candidates
Ng, Y. L., Salim, C. K., & Chu, J. J. H. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107930 · Cited by 158
“Pathway mapping has proved to be a major cornerstone in drug repurposing during this pandemic (Mousavi, Rahmanian, & Sami, 2020; Zhou et al., 2020).”
The Role of Artificial Intelligence in Fighting the COVID-19 Pandemic
Piccialli, F., Cola, V. S. D., Giampaolo, F., & Cuomo, S. (2021) · Information Systems Frontiers · doi:10.1007/s10796-021-10131-x · Cited by 153
Translational precision medicine: an industry perspective
Hartl, D., Luca, V. D., Kostikova, A., Laramie, J. M., Kennedy, S., Ferrero, E., Siegel, R. W., Fink, M., Ahmed, S., Millholland, J. M., et al. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-021-02910-6 · Cited by 161
“development concepts are getting higher traction; (ii) large longitudinal datasets collected from COVID19 patients are systematically analyzed and offer great potential for multi-omics [173–175] and AI-based analyses [169, 176–178], supporting diagnosis, basic disease understanding, endotyping, image analysis, drug ta…”
BackgroundGkeredakis, M., Lifshitz-Assaf, H., & Barrett, M. (2021) · Information and Organization · doi:10.1016/j.infoandorg.2021.100344 · Cited by 173
“In particular, as de-novo drug discovery had been perceived as almost impossible, there was an increase in development of AI for drug repurposing (Zhou, Wang, Tang, Nussinov, & Cheng, 2020).”
Bang, D., Lim, S., Lee, S., & Kim, S. (2023) · Nature Communications · doi:10.1038/s41467-023-39301-y · Cited by 132
Repurposing of CNS drugs to treat COVID-19 infection: targeting the sigma-1 receptor
Hashimoto, K. (2021) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-020-01231-x · Cited by 118
Current Strategies of Antiviral Drug Discovery for COVID-19
Mei, M., & Tan, X. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.671263 · Cited by 111
Biomolecular modeling thrives in the age of technology
Tamar Schlick, A., & Portillo‐Ledesma, S. (2021) · Nature Computational Science · doi:10.1038/s43588-021-00060-9 · Cited by 114
Face mask detection using MobileNet and Global Pooling Block
Isunuri, B. V., Kakarla, J., & Prakash, S. (2020) · IEEE Conference on Information and Communication Technology (CICT) · doi:10.1109/cict51604.2020.9312083 · Cited by 108
“[3] have presented how to use artificial intelligence for accelerating drug repurposing or repositioning.”
Abu-Salih, B., Al‐Qurishi, M., Alweshah, M., AL-Smadi, M., Alfayez, R., & Saadeh, H. (2023) · Journal Of Big Data · doi:10.1186/s40537-023-00774-9 · Cited by 130
“It aims to reuse existing drugs to treat emerging diseases (such as COVID-19) thereby reducing both drug development timelines and the associated costs [54].”
BackgroundCovid-19 and Artificial Intelligence: Genome sequencing, drug development and vaccine discovery
Bagabir, S. A., Ibrahim, N. K., Bagabir, H. A., & Ateeq, R. H. (2022) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2022.01.011 · Cited by 106
“In addition, AI is a core of advanced technologies where the discovered therapy would be available for a clinical trial, and when it is approved it uses for health care [33].”
The metaverse in current digital medicine
Sun, M., Xie, L., Liu, Y., Li, K., Jiang, B., Lu, Y., Yang, Y., Yu, H., Song, Y., Bai, C., et al. (2022) · Clinical eHealth · doi:10.1016/j.ceh.2022.07.002 · Cited by 104
Arora, G., Joshi, J., Mandal, R. S., Shrivastava, N., Virmani, R., & Sethi, T. (2021) · Pathogens · doi:10.3390/pathogens10081048 · Cited by 117
A heterogeneous network embedding framework for predicting similarity-based drug-target interactions
An, Q., & Yu, L. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbab275 · Cited by 100
Alsalem, M. A., Mohammed, R. T., Albahri, O. S., Zaidan, A. A., Alamoodi, A. H., Dawood, K. A., Alnoor, A., Albahri, A. S., Zaidan, B. B., Aickelin, U., et al. (2021) · International Journal of Intelligent Systems · doi:10.1002/int.22699 · Cited by 94
Ahmed, F., Soomro, A. M., Salih, A. R. C., Samantasinghar, A., Asif, A., Kang, I. S., & Choi, K. H. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113350 · Cited by 92
Naik, N., Hameed, B. M. Z., Sooriyaperakasam, N., Vinayahalingam, S., Patil, V., Smriti, K., Saxena, J., Shah, M., Ibrahim, S., Singh, A., et al. (2022) · Frontiers in Digital Health · doi:10.3389/fdgth.2022.919985 · Cited by 93
Abdeldayem, O. M., Dabbish, A. M., Habashy, M. M., Mostafa, M. K., Elhefnawy, M., Amin, L., Al-Sakkari, E. G., Ragab, A., & Rene, E. R. (2021) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2021.149834 · Cited by 93
“Furthermore, ML and deep learning (DL) models can help fast drug repurposing or even drug discovery for a novel disease, such as in COVID-19 (Ivanov et al., 2020; Jain et al., 2021; Mohanty et al., 2020; Zhou et al., 2020).”
Blockchain, artificial intelligence, and healthcare: the tripod of future—a narrative review
Bathula, A., Gupta, S. K., Merugu, S., Saba, L., Khanna, N. N., Laird, J. R., Sanagala, S. S., Singh, R. K., Garg, D., Fouda, M. M., et al. (2024) · Artificial Intelligence Review · doi:10.1007/s10462-024-10873-5 · Cited by 110
Zhou, Y., Fang, J., Bekris, L. M., Kim, Y. H., Pieper, A. A., Leverenz, J. B., Cummings, J. L., & Cheng, F. (2021) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00760-w · Cited by 85
Ünal, M. A., Bayrakdar, F., Nazır, H., Beşbinar, Ö., Gürcan, C., Lozano, N., Arellano, L. M., Yalçın, S., Panatli, O., Çelik, D., et al. (2021) · Small · doi:10.1002/smll.202101483 · Cited by 81
Repurposing drugs for the management of COVID-19
Cusinato, J., Cau, Y., Calvani, A. M., & Mori, M. (2020) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2021.1861248 · Cited by 78
Shahid, O., Nasajpour, M., Pouriyeh, S., Parizi, R. M., Han, M., Valero, M., Li, F., Aledhari, M., & Sheng, Q. Z. (2021) · Journal of Biomedical Informatics · doi:10.1016/j.jbi.2021.103751 · Cited by 80
“We have already seen ML methods and techniques like SVM, RNN and Bayesian Classifiers being used for drug discovery and repurposing [41,244].”
SAveRUNNER: an R-based tool for drug repurposing
Fiscon, G., & Paci, P. (2021) · BMC Bioinformatics · doi:10.1186/s12859-021-04076-w · Cited by 78
The Promise of AI in Detection, Diagnosis, and Epidemiology for Combating COVID-19: Beyond the Hype
Abdulkareem, M., & Petersen, S. E. (2021) · Frontiers in Artificial Intelligence · doi:10.3389/frai.2021.652669 · Cited by 83
Dong, J., Wu, H., Zhou, D., Li, K., Zhang, Y., Ji, H., Tong, Z., Lou, S., & Liu, Z. (2021) · Journal of Medical Systems · doi:10.1007/s10916-021-01757-0 · Cited by 74
Fan, K., Cheng, L., & Li, L. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbab271 · Cited by 79
Manjunath, S. H., & Thimmulappa, R. K. (2021) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2021.09.009 · Cited by 76
“Based on the knowledge gained from a mechanistic understanding of COVID-19 pathogenesis and big-data analysis using arti fi cial intelligence, several approved drugs are being repositioned for COVID-19 treatment [6].”
Rodríguez‐Rodríguez, I., Rodríguez, J., Shirvanizadeh, N., Ortíz, A., & Pardo-Quiles, D. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18168578 · Cited by 82
The machine learning life cycle and the cloud: implications for drug discovery
Spjuth, O., Frid, J., & Hellander, A. (2021) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2021.1932812 · Cited by 67
“It is envisioned that AI will increase productivity and reduce attrition in drug discovery [12], a hypothesis that has been strengthened during the COVID-19 pandemic [13–15].”
BackgroundThe Potential Applications of Artificial Intelligence in Drug Discovery and Development
Farghali, H., Kutinová Canová, N., & Arora, M. (2021) · Physiological Research · doi:10.33549/physiolres.934765 · Cited by 72
“As discussed by Zhou et al. (2020) about the use of AI models in precision medicine, AI models can accelerate COVID-19 drug repurposing.”
BackgroundMethodArtificial Intelligence in Drug Design: Algorithms, Applications, Challenges and Ethics
Arabi, A. A. (2021) · Future Drug Discovery · doi:10.4155/fdd-2020-0028 · Cited by 75
Tripathi, N., Goshisht, M. K., Sahu, S. K., & Arora, C. (2021) · Molecular Diversity · doi:10.1007/s11030-021-10237-z · Cited by 75
Kalakoti, Y., Yadav, S., & Sundar, D. (2022) · ACS Omega · doi:10.1021/acsomega.1c05203 · Cited by 73
Drug Design and Disease Diagnosis: The Potential of Deep Learning Models in Biology
Sreeraman, S., Mayuri, K., Kushwah, R. B. S., Sundaram, V., Veluchamy, A., Anand, T., & Saravanan, K. M. (2023) · Current Bioinformatics · doi:10.2174/1574893618666230227105703 · Cited by 72
Influential Usage of Big Data and Artificial Intelligence in Healthcare
Yang, Y. C., Islam, S. U., Noor, A., Khan, S., Afsar, W., & Nazir, S. (2021) · Computational and Mathematical Methods in Medicine · doi:10.1155/2021/5812499 · Cited by 68
“The study is a strong proof for the use of AI-assisted tools for drugs and repayment for human diseases, including COVID-19 in times of fatal disease [11].”
MethodRetractedWu, H., Lu, X., & Wang, H. (2023) · JMIR AI · doi:10.2196/38397 · Cited by 69
“At the molecular level, protein structure prediction, novel nucleic acid testing, drug repurposing, and drug discovery all rely on AI and deep-learning algorithms [7-9].”
BackgroundAhmed, F., Kang, I. S., Kim, K. H., Asif, A., Rahim, C. S. A., Samantasinghar, A., Memon, F. H., & Choi, K. H. (2023) · Journal of Medical Virology · doi:10.1002/jmv.28693 · Cited by 75
“In this section ML, DL, and other approaches ‐ based drug repurposing approaches 24,171 – 173 are mentioned along with some examples.”
BackgroundThe Role of Chatbots in Enhancing Customer Experience: Literature Review
Bakkouri, B. E., Raki, S., & Belgnaoui, L. T. (2022) · Procedia Computer Science · doi:10.1016/j.procs.2022.07.057 · Cited by 88
Padhi, A., Agarwal, A., Saxena, S. K., & Katoch, C. D. S. (2023) · VirusDisease · doi:10.1007/s13337-023-00841-y · Cited by 75
“The integration of AI not only accelerated the identification process but also reduced the dependency on time-consuming wet-lab experiments, signifying a more efficient approach towards therapeutic discoveries [27].”
BackgroundMachine Learning Empowering Drug Discovery: Applications, Opportunities and Challenges
Qi, X., Zhao, Y., Qi, Z., Hou, S., & Chen, J. (2024) · Molecules · doi:10.3390/molecules29040903 · Cited by 75
“The template-based approach involves systematically comparing the target molecule with a set of templates, each representing alternative substructure patterns that occur during a chemical reaction [105].”
BackgroundMethodApplication of Artificial Intelligence in COVID-19 Pandemic: Bibliometric Analysis
Islam, M. M., Poly, T. N., Alsinglawi, B. S., Lin, L., Chien, S.-C., Liu, J., & Jian, W. (2021) · Healthcare · doi:10.3390/healthcare9040441 · Cited by 66
“Rank Author Journal Citations, n Strength 1 Huang Chaolin et al. 2020 Lancet 150 905 2 Wei-jie Guan et al. 2020 The New England Journal of Medicine 81 403 3 Kaiming He et al. 2016 IEEE Conference on Computer Vision and Pattern Recognition 78 688 4 Tao Ai et al. 2020 Radiology 75 616 5 Nanshan Chen et al. 2020 Lancet 7…”
InfluentialCheng, F., Wang, F., Tang, J., Zhou, Y., Fu, Z., Zhang, P., Haines, J. L., Leverenz, J. B., Gan, L., Hu, J., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101379 · Cited by 63
Self-citationAntisense Oligonucleotide-Based Therapy of Viral Infections
Tarn, W., Cheng, Y., Ko, S.-H., & Huang, L. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13122015 · Cited by 68
Expert-Augmented computational drug repurposing identified baricitinib as a treatment for COVID-19
Smith, D. P., Oechsle, O., Rawling, M. J., Savory, E., Lacoste, A. M. B., & Richardson, P. J. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.709856 · Cited by 62
Comprehensive Survey of Using Machine Learning in the COVID-19 Pandemic
El-Rashidy, N. M., Abdelrazek, S. M., Abuhmed, T., Amer, E., Ali, F., Hu, J. W., & El–Sappagh, S. (2021) · Diagnostics · doi:10.3390/diagnostics11071155 · Cited by 62
“AI also can speed up the pace by extracting useful data for drug repurposing [160].”
BackgroundKhoury, P., Srinivasan, R., Kakumanu, S., Ochoa, S., Keswani, A., Sparks, R., & Rider, N. L. (2022) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2022.01.047 · Cited by 67
“ML approaches are being leveraged to classify immune cell stress features and predict antiviral responses for drug repurposing efforts.(33,34) Lastly, ML is being coupled with reverse vaccinology to predict viral-host protein interactions and identify druggable targets and vaccine epitopes.”
BackgroundDevelopment and application of therapeutic antibodies against COVID-19
Lin, N., Abagna, H. B., Jiang, Q., Liu, S., & Huang, J. H. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.59149 · Cited by 61
Emerging Therapeutic Approaches to Combat COVID-19: Present Status and Future Perspectives
Vivekanandhan, K., Poornima, S., Barabadi, H., Arumugam, V., Raj, D. D. R. D. P., Manikandan, S., Subbaiya, R., Anand, K., Pandi, B., Chandrasekaran, B., et al. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.604447 · Cited by 60
Bompelli, A., Wang, Y., Wan, R., Singh, E., Zhou, Y., Xu, L., Oniani, D., Kshatriya, B. S. A., Balls-Berry, J. (. E., & Zhang, R. (2021) · Health Data Science · doi:10.34133/2021/9759016 · Cited by 58
“Afshar et al. [46] used LDA to identify subtypes of patients with opioid misuse whereas Cui et al. [67] used K-means clustering and principal component analysis (PCA) to analyze and discover latent clusters in COVID-19 patients.”
MethodInfluentialMajeed, A., & Hwang, S. O. (2021) · Symmetry · doi:10.3390/sym14010016 · Cited by 73
Artificial intelligence-driven drug repurposing and structural biology for SARS-CoV-2
Prasad, K., & Kumar, V. (2021) · Current Research in Pharmacology and Drug Discovery · doi:10.1016/j.crphar.2021.100042 · Cited by 58
Machine learning and network medicine approaches for drug repositioning for COVID-19
Santos, S. D. S., Torres, M., Galeano, D., Sánchez, M. D. M., Cernuzzi, L., & Paccanaro, A. (2021) · Patterns · doi:10.1016/j.patter.2021.100396 · Cited by 57
Abbas, S. R., Seol, H., Abbas, Z., & Lee, S. W. (2025) · Healthcare · doi:10.3390/healthcare13141642 · Cited by 64
“This level of functionality is inspired by cognitive psychology, where ToM is central to empathetic and cooperative behavior [88].”
Data science approaches to confronting the COVID-19 pandemic: a narrative review
Zhang, Q., Gao, J., Wu, J. T. K., Cao, Z., & Zeng, D. D. (2021) · Philosophical Transactions of the Royal Society A Mathematical Physical and Engineering Sciences · doi:10.1098/rsta.2021.0127 · Cited by 53
Partner-Specific Drug Repositioning Approach Based on Graph Convolutional Network
Sun, X., Wang, B., Zhang, J., & Li, M. (2022) · IEEE Journal of Biomedical and Health Informatics · doi:10.1109/jbhi.2022.3194891 · Cited by 53
“disease (COVID-19) [2], [3], suggesting that drug repositioning is a promising way to fight against diseases with no curative treatment.”
BackgroundTutsoy, Ö. (2021) · IEEE Access · doi:10.1109/access.2021.3078080 · Cited by 53
“…from the chest Computed Tomography (CT) [19], to speed up the Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) tests used for the diagnosis of the COVID-19 [20], to halt viral replication by designing new molecules [21], and to re-evaluate the drugs used for the COVID-19 treatments [22].”
BackgroundMethodRecent advances from computer-aided drug design to artificial intelligence drug design
Wang, K., Huang, Y., Wang, Y., You, Q., & Wang, L. (2024) · RSC Medicinal Chemistry · doi:10.1039/d4md00522h · Cited by 58
A BioID-Derived Proximity Interactome for SARS-CoV-2 Proteins
May, D. G., Martin‐Sancho, L., Anschau, V., Liu, S. N., Chrisopulos, R. J., Scott, K. L., Halfmann, C. T., Peña, R. D., Pratt, D. R., Campos, A. R., et al. (2022) · Viruses · doi:10.3390/v14030611 · Cited by 55
HGTDR: Advancing drug repurposing with heterogeneous graph transformers
Gharizadeh, A., Abbasi, K., Ghareyazi, A., Mofrad, M. R. K., & Rabiee, H. R. (2024) · Bioinformatics · doi:10.1093/bioinformatics/btae349 · Cited by 49
“Drug repurposing, defined as identifying new uses for approved drugs, has emerged as a viable solution to these issues (Zhou et al. 2020).”
BackgroundEl-Behery, H., Attia, A.-F. A., El-Fishawy, N. A., & Torkey, H. (2021) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2021.107536 · Cited by 45
“Another research in (Zhou et al., 2020) provides guidelines on how to use artificial intelligence (AI) to accelerate the redefinition or repositioning of drugs and show which AI approaches are not only massive but also necessary.”
BackgroundArtificial Intelligence in Accelerating Drug Discovery and Development
Tripathi, A., Misra, K., Dhanuka, R., & Singh, J. P. (2022) · Recent Patents on Biotechnology · doi:10.2174/1872208316666220802151129 · Cited by 45
Ebrahimi, K. S., Ansari, M., Moghaddam, M. S. H., Ebrahimi, Z., Salehi, Z., Shahlaei, M., & Moradi, S. (2021) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2021.104613 · Cited by 48
Artificial intelligence for COVID-19: battling the pandemic with computational intelligence
Xu, Z., Su, C., Xiao, Y., & Wang, F. (2021) · Intelligent Medicine · doi:10.1016/j.imed.2021.09.001 · Cited by 48
Genome‐scale metabolic modeling reveals SARS‐CoV‐2‐induced metabolic changes and antiviral targets
Cheng, K., Martin‐Sancho, L., Pal, L. R., Pu, Y., Riva, L., Yin, X., Sinha, S., Nair, N. U., Chanda, S. K., & Ruppin, E. (2021) · Molecular Systems Biology · doi:10.15252/msb.202110260 · Cited by 43
Amrollahi, F., Shashikumar, S. P., Holder, A. L., & Nemati, S. (2022) · Scientific Reports · doi:10.1038/s41598-022-12497-7 · Cited by 45
AI-Driven Drug Discovery for Rare Diseases
Gangwal, A., & Lavecchia, A. (2024) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.4c01966 · Cited by 49
Das, J. K., Tradigo, G., Veltri, P., Guzzi, P. H., & Roy, S. (2020) · Briefings in Bioinformatics · doi:10.1093/bib/bbaa420 · Cited by 44
“As discussed in Section 6, drug repurposing is a crucial methodology for COVID-19-related therapies, since the adoption of the classical and very time-consuming drug-discovery approach [129] is unfeasible.”
BackgroundCombination therapies for COVID‐19: An overview of the clinical trials landscape
Akinbolade, S., Coughlan, D., Fairbairn, R., McConkey, G. A., Powell, H., Ogunbayo, O. J., & Craig, D. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15089 · Cited by 44
“dent treatments to increase therapeutic efficacy in a much wider population and across the disease pathway.(8) There are several compelling reasons for exploring combination therapies for COVID-19 treatment: (i) different mechanisms of action in order to treat different pathologies of the disease such as combining an…”
BackgroundDiscovery of SARS-CoV-2 main protease covalent inhibitors from a DNA-encoded library selection
Ge, R., Shen, Z., Yin, J., Chen, W., Zhang, Q., An, Y., Tang, D., Satz, A. L., Su, W., & Kuai, L. (2022) · SLAS DISCOVERY · doi:10.1016/j.slasd.2022.01.001 · Cited by 43
Gatti, M., Turrini, E., Raschi, E., Sestili, P., & Fimognari, C. (2021) · Pharmaceuticals · doi:10.3390/ph14080738 · Cited by 45
Review of Oxygenation with Nanobubbles: Possible Treatment for Hypoxic COVID-19 Patients
Afshari, R., Akhavan, O., Hamblin, M. R., & Varma, R. S. (2021) · ACS Applied Nano Materials · doi:10.1021/acsanm.1c01907 · Cited by 43
Harren, T., Gutermuth, T., Grebner, C., Heßler, G., & Rarey, M. (2024) · Wiley Interdisciplinary Reviews Computational Molecular Science · doi:10.1002/wcms.1716 · Cited by 46
AI in Orthopedic Research: A Comprehensive Review
Mısır, A., & Yuce, A. (2025) · Journal of Orthopaedic Research® · doi:10.1002/jor.26109 · Cited by 46
“ML algorithms — especially deep neural networks and graph convolutional networks — have demonstrated the ability to predict drug ‐ target interactions and toxicity profiles with high accuracy, reducing the cost and time associated with traditional screening methods [92, 93].”
Fawaz, A., Ferraresi, A., & Isidoro, C. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13111590 · Cited by 46
Vivarelli, S., Candido, S., Caruso, G., Falzone, L., & Libra, M. (2020) · Cancers · doi:10.3390/cancers12123636 · Cited by 41
Chee, M. L., Ong, M. E. H., Siddiqui, F. J., Zhang, Z., Lim, S. L., Ho, A. F. W., & Liu, N. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18094749 · Cited by 40
Nawrot-Hadzik, I., Żmudziński, M., Matkowski, A., Preißner, R., Kęsik-Brodacka, M., Hadzik, J., Drąg, M., & Abel, R. (2021) · Pharmaceuticals · doi:10.3390/ph14080742 · Cited by 45
Metadata
- Authors
- Zhou, Y., Wang, F., Tang, J., Nussinov, R., & Cheng, F.
- Affiliations
- Cleveland Clinic (US)
- Cornell University (US)
- HEC Montréal (CA)
- Tel Aviv University (IL)
- Corresponding author
- Cheng, Feixiong
- Venue
- The Lancet Digital Health
- Publisher
- Elsevier BV
- Published
- 2020-12
- Volume
- 2
- Issue
- 12
- Pages
- e667-e676
- ISSN
- 2589-7500 (ISSN-L)
- PMC
- PMC7500917
- OpenAlex
- W3087156149
- Cited by
- 636
- References
- 89
- Citations by year
- 2026: 50 · 2025: 74 · 2024: 73 · 2023: 131 · 2022: 117 · 2021: 173 · 2020: 18
- FWCI
- 9.64
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- The Lancet Digital Health (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- reponame:Expeditio Repositorio Institucional UJTL
- Funders
- National Science Foundation (2027970, 1750326, HHSN261200800001E)
- Cleveland Clinic
- Frederick National Laboratory for Cancer Research (HHSN261200800001E.)
- National Institutes of Health (#HHSN261200800001E, COVID-19, HHSN261200800001C)
- National Institute on Aging (R01AG066707)
- National Heart, Lung, and Blood Institute (R00HL138272, HHSN261200800001E)
- Office of Naval Research (N00014-18-1-2585, N00014)
- National Cancer Institute (HHSN261200800001E))
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Health Sciences › Medicine › Health Informatics › Artificial Intelligence in Healthcare and Education
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › COVID-19 diagnosis using AI
- Keywords
- drug repurposing, COVID-19 pandemic, artificial intelligence, network medicine, precision medicine, drug target identification, drug development acceleration, big data
- MeSH terms
- SARS-CoV-2, COVID-19 Drug Treatment, Algorithms, Antiviral Agents, Artificial Intelligence, Drug Therapy, Combination, Humans, Treatment Outcome, Drug Discovery, Drug Repositioning
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
